{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:15:05Z","timestamp":1783358105646,"version":"3.54.6"},"reference-count":16,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NeuroSci"],"abstract":"<jats:p>Background: Monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway represent an effective preventive treatment for chronic migraine, including in patients with multiple prior therapeutic failures. However, a substantial proportion of patients exhibit a suboptimal or delayed response. The role of personality traits in modulating treatment response remains poorly understood. Methods: In this prospective observational study, adults with chronic migraine received anti-CGRP monoclonal antibodies and were followed for 12 months. Monthly headache days (MHDs), monthly acute medication use (MAM), and disability scores (MIDAS and HIT-6) were recorded at baseline and at 3, 6, and 12 months. Responders were defined as patients achieving a \u226550% reduction in monthly headache days (MHDs) compared with baseline. Changes in disability measures were evaluated as secondary clinical outcomes. Personality traits were assessed using the Millon Clinical Multiaxial Inventory-III. Results: Thirty-eight patients were included, of whom 71% had medication overuse headaches. Responder rates increased over time (31.6% at 3 months and 39.5% at 12 months). Histrionic traits (37.5% vs. 6.7%, p = 0.048) and dysthymic features (21.4% vs. 0%, p = 0.046) were significantly more prevalent among non-responders. Conclusions: Histrionic and dysthymic personality features were associated with a lower likelihood of response to anti-CGRP therapy in patients with chronic migraine. Given the exploratory design, limited sample size, and absence of correction for multiple comparisons, these findings should be considered preliminary and hypothesis-generating. Further studies in larger cohorts are needed to confirm these observations.<\/jats:p>","DOI":"10.3390\/neurosci7040077","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:56:42Z","timestamp":1783349802000},"page":"77","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the Impact of Personality Traits on Response to Anti-CGRP Therapies: Insights from a Pilot Study"],"prefix":"10.3390","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9945-4042","authenticated-orcid":false,"given":"Chiara","family":"Zilli","sequence":"first","affiliation":[{"name":"Department of Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5910-6043","authenticated-orcid":false,"given":"Giada","family":"Giuliani","sequence":"additional","affiliation":[{"name":"Department of Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Tancredi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2819-4671","authenticated-orcid":false,"given":"Mariangela","family":"Fratino","sequence":"additional","affiliation":[{"name":"Department of Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Pitzalis","sequence":"additional","affiliation":[{"name":"Department of Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Altieri","sequence":"additional","affiliation":[{"name":"Department of Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","article-title":"Migraine remains second among the world\u2019s causes of disability, and first among young women: Findings from GBD2019","volume":"21","author":"Steiner","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Hong, J.B., Lange, K.S., Overeem, L.H., Triller, P., Raffaelli, B., and Reuter, U. (2023). A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response. Pharmaceuticals, 16.","DOI":"10.3390\/ph16070934"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e16106","DOI":"10.1111\/ene.16106","article-title":"Depression and treatment with anti-calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraine","volume":"31","author":"MaassenVanDenBrink","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1007\/s10072-025-08372-8","article-title":"Anti-CGRP monoclonal antibodies, migraine and mood disorders: An observational study","volume":"46","author":"Bolchini","year":"2025","journal-title":"Neurol. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Galvez-S\u00e1nchez, C.M., and Montoro Aguilar, C.I. (2022). Migraine and Neuroticism: A Scoping Review. Behav. Sci., 12.","DOI":"10.3390\/bs12020030"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"107641","DOI":"10.1016\/j.clineuro.2023.107641","article-title":"A cross-sectional study on the personality traits of episodic and chronic migraine patients","volume":"227","author":"Albayrak","year":"2023","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.1007\/s10072-022-06251-0","article-title":"Personality traits and efficacy of anti-CGRP monoclonal antibodies in migraine prevention","volume":"43","author":"Lovati","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1080\/00223890701357217","article-title":"Contributions to the Dimensional Assessment of Personality Disorders Using Millon\u2019s Model and the Millon Clinical Multiaxial Inventory (MCMI\u2013III)","volume":"89","author":"Strack","year":"2007","journal-title":"J. Personal. Assess."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1212\/WNL.0000000000207292","article-title":"Late Response to Anti-CGRP Monoclonal Antibodies in Migraine: A Multicenter Prospective Observational Study. Italian Migraine Registry study group","volume":"101","author":"Barbanti","year":"2023","journal-title":"Neurology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s42003-024-05937-9","article-title":"CGRP causes anxiety via HP1\u03b3-KLF11-MAOB pathway and dopamine in the dorsal hippocampus","volume":"7","author":"Fujiwara","year":"2024","journal-title":"Commun. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1017\/neu.2018.31","article-title":"CGRP in a gene-environment interaction model for depression: Effects of antidepressant treatment","volume":"31","author":"Angelucci","year":"2019","journal-title":"Acta Neuropsychiatr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s10194-021-01333-4","article-title":"Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: Data from an open label long-term prospective study","volume":"22","author":"Bottiroli","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_13","unstructured":"Diener, E., and Richard, E.L. (2019). Personality Traits. General Psychology: Required Reading, Noba Project."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10072-013-1379-8","article-title":"Personality traits, personality disorders, and migraine: A review","volume":"34","author":"Davis","year":"2013","journal-title":"Neurol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"A105","DOI":"10.1186\/1129-2377-16-S1-A105","article-title":"Psychodynamic functioning in chronic headache patients: A short-term psychodynamic psychotherapy (STPP) study","volume":"16","author":"Petolicchio","year":"2015","journal-title":"J. Headache Pain"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Klan, T., Gaul, C., Liesering-Latta, E., Both, B., Held, I., Hennemann, S., and Witth\u00f6ft, M. (2022). Efficacy of Cognitive-Behavioral Therapy for the Prophylaxis of Migraine in Adults: A Three-Armed Randomized Controlled Trial. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.852616"}],"container-title":["NeuroSci"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2673-4087\/7\/4\/77\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:20:44Z","timestamp":1783354844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2673-4087\/7\/4\/77"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["neurosci7040077"],"URL":"https:\/\/doi.org\/10.3390\/neurosci7040077","relation":{},"ISSN":["2673-4087"],"issn-type":[{"value":"2673-4087","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]}}}